Lymphocyte subpopulations (mean, SD)
| Subpopulation (cells ×106/l) | Pre-PM | 30 minutes post-PM | 2 minutes post-RBB | 15 minutes post-RBB | 45 minutes post-RBB | |
|---|---|---|---|---|---|---|
| M = midazolam. P = placebo. D = significant differences between midazolam group and placebo group. PM = premedication, RBB = retrobulbar block. Crosses denote significant differences within one group, compared to the previous blood sample (*p<0.05; **p<0.01). | ||||||
| B cells | P | 308 (125) | 303 (146) | 286 (144) | 309 (141) | 287 (129) |
| M | 292 (93) | 291 (83) | 299 (87) | 308 (87) | 305 (77) | |
| CD4+ cells | P | 792 (163) | 725 (199)* | 725 (221) | 728 (209) | 694 (231) |
| (helper/inducer T cells) | M | 587 (200) | 552 (220) | 568 (215) | 578 (246) | 588 (253) |
| D | p=0.003 | p=0.03 | ||||
| CD8+ cells | P | 403 (223) | 346 (165)* | 374 (245) | 344 (170) | 318 (194) |
| (cytotoxic/suppressor T cells) | M | 296 (138) | 230 (103)* | 240 (125) | 239 (131) | 236 (129) |
| D | p=0.02 | |||||
| CD3+ CD16/56+ cells | P | 164 (125) | 140 (100) | 163 (162) | 144 (108) | 149 (119) |
| (cytotoxic, not-MHC-restricted T cells) | M | 159 (108) | 119 (82)** | 128 (85) | 126 (95) | 130 (98) |
| CD4+ CD8+ cells | P | 35 (30) | 30 (24) | 33 (37) | 30 (25) | 31 (30) |
| (immature T cells) | M | 37 (36) | 30 (32)* | 31 (26) | 30 (31) | 31 (27) |
| CD3− CD16/56+ cells | P | 377 (160) | 290 (84)** | 354 (133)** | 304 (131)* | 283 (130) |
| (NK cells) | M | 295 (169) | 191 (96)** | 203 (80) | 178 (93) | 191 (97) |
| D | p=0.01 | p=0.002 | p=0.01 | |||